阿诺医药是一家临床阶段的全球性生物制药公司，致力于开发差异化、创新性的肿瘤免疫治疗药物，涵盖4款临床阶段及多款临床前候选药物。
Location: China, Zhejiang, Hangzhou City
Employees: 11-50
Total raised: $153M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | triwise | en.triwise... |
| - | Matrix Par... | matrixpart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.07.2021 | Series D | $100M | - |
| 05.07.2018 | Series B | $53M | - |
Mentions in press and media 12
| Date | Title | Description |
| 15.03.2022 | Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs | NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 15, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, is pleased to welc... |
| 21.02.2022 | Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology | NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announc... |
| 26.01.2022 | Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025) | NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that it h... |
| 06.01.2022 | Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors | NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 6, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the f... |
| 08.09.2021 | Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors | NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Ph... |
| 15.07.2021 | China's Adlai Nortye nabs another cool $100M for its immuno-oncology pipeline | Adlai Nortye has added $100 million to the bank to fuel a phase 3 clinical trial of its lead program, gained through a 2018 deal with Novartis, and a pipeline of nine other drug candidates. In April, the company said it dosed the first pati... |
| 15.07.2021 | China's Adlai Nortye nabs another cool $100M for its immuno-oncology pipeline | Adlai Nortye has added $100 million to the bank to fuel a phase 3 clinical trial of its lead program, gained through a 2018 deal with Novartis, and a pipeline of nine other drug candidates. The Chinese biopharmaceutical inked the financing,... |
| 13.07.2021 | Chinese biopharma firm Adlai Nortye bags $100m in a Series D round | Premium Hangzhou Adlai Nortye Biopharma Co., Ltd, a Chinese clinical-stage biopharmaceutical firm that makes immuno-oncology medicines, has raked in $100 million in a Series D round, according to a company statement on Tuesday. Continue rea... |
| 13.07.2021 | Chinese biopharma firm Adlai Nortye bags $100m in a Series D round | Hangzhou Adlai Nortye Biopharma Co., Ltd, a Chinese clinical-stage biopharmaceutical firm that makes immuno-oncology medicines, has raked in $100 million in a Series D round, according to a company statement on Tuesday. CMG-SDIC Capital and... |
| 31.08.2020 | Chinese biopharma firm Adlai Nortye nets $100m in Series C round | Premium Adlai Nortye, a China-based clinical-stage biopharmaceutical firm that develops immuno-oncology medicines, on Monday announced the completion of nearly $100 million in a Series C round of financing. Continue reading this story with ... |
Show more